进展期胃癌术后早期腹腔温热灌注化疗疗效的临床研究

[目的]探讨进展期胃癌术后早期腹腔温热灌注化疗对于改善患者生存率的意义。[方法]159例L3、L4（Ⅱ-Ⅳ期）胃癌手术患者，对比研究腹腔温热化疗组化疗方案（78例）与对照组（81例）术后并发症、复发转移率和3年生存率。[结果]并发症比较：腹腔温热化疗组腹胀及肌酐升高的发生率均显著高于对照组（92.3％vs．14．8％，P〈0．05；11．5％VS．1．2％，P〈0．05），但治疗后均恢复正常。术后复发转移：腹腔温热化疗组腹膜腔复发转移率显著低于对照组（32．1％vs．54-3％，P〈0．05）。腹腔温热化疗组3年生存率显著高于对照组（52．6％VS．32．1％，P=0．003）。[结论]进展期胃癌术后早期进行腹腔温热灌注化疗能够减少腹膜腔复发转移，提高生存率。

Clinical Study on Early Postoperative Hyperthemic Peritoneal Chemoperfusion for Advanced Gastric Cancer

[Purpose]To explore the role of early postoperative hyperthermic peritoneal chemoperfusion on improving survival rate for gastric cancer. [Methods] One hundred and fifty nine cases with postoperative gastric cancer T3 or T4 stage were divided into hyperthemic peritoneal chemoperfusion group（78 cases） and control group （81 cases）. Complication, recurrence metastasis and 3-year survival rates in two groups were compared. [Results ] The complication of tympanites and increased creatinine in chemotherapy group was more than that in control group（92.3% vs. 14.8%, P〈0.05; 11.5% vs. 1.2%, P〈0.05）. These complications all recovered to normal after treatment. The intraperitoneal recurrence rate in chemotherapy group was lower than that in control group （32.1% vs. 54.3%, P〈0.05）. Three-year survival rate in chemotherapy group was higher than that in control group （52.6% vs. 32.1%, P=0.003）. [Conclusion] Postoperative hyperthermic intraperitoneal chemopeffusion can reduce peritoneal recurrence, metastasis and improve survival rate in gastric cancer.